Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.04 USD | +5.47% | +9.73% | +97.22% |
05-14 | Stephens Starts Inovio Pharmaceuticals With Overweight Rating, $20 Price Target | MT |
05-13 | Transcript : Inovio Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+97.22% | 296M | |
+26.03% | 49.18B | |
+0.88% | 42.11B | |
+50.07% | 40.37B | |
-5.26% | 28.85B | |
+13.02% | 26.09B | |
-22.19% | 18.71B | |
+8.35% | 13.26B | |
+31.72% | 12.32B | |
+0.01% | 11.99B |
- Stock Market
- Equities
- INO Stock
- News Inovio Pharmaceuticals, Inc.
- Inovio Pharmaceuticals : RBC Capital Adjusts Inovio Pharmaceuticals PT to $11 From $12, Maintains Sector Perform - Speculative Risk